The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794
- PMID: 18930488
- PMCID: PMC3512115
- DOI: 10.1016/j.juro.2008.08.037
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794
Abstract
Purpose: From the randomized study Southwest Oncology Group 8794 we evaluated the effect of seminal vesicle involvement on outcomes and whether those patients benefited from post-prostatectomy adjuvant radiation therapy.
Materials and methods: Southwest Oncology Group study 8794 randomized high risk patients (with seminal vesicle positive disease and/or capsular penetration and/or positive margins) to radiation vs observation after prostatectomy. A total of 431 subjects with pathologically advanced prostate cancer were randomized.
Results: Median followup was 12.2 years. Of the patients 139 had seminal vesicle involvement with or without capsular penetration and/or positive margins. Compared to the 286 patients with seminal vesicle negative disease there was poorer 10-year biochemical failure-free survival (33% for seminal vesicle negative and 22% for seminal vesicle positive, p = 0.04), metastasis-free survival (70% and 56%, respectively, p = 0.005) and overall survival (10-year overall survival 74% and 61%, respectively, p = 0.02) for those with seminal vesicle positive disease. Patients with seminal vesicle positive disease who received adjuvant radiation compared to observation realized an improvement in 10-year biochemical failure-free survival from 12% to 36% (p = 0.001), in 10-year overall survival from 51% to 71% (p = 0.08) and in metastasis-free survival from 47% to 66% (p = 0.09), respectively.
Conclusions: Although seminal vesicle involvement is a negative prognostic factor, long-term control is possible especially if patients are given adjuvant radiation therapy. This therapy appears to be effective in patients with seminal vesicle involvement.
Figures



References
-
- Schellhammer PF. Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology. 1988 Mar;31(3):191–7. - PubMed
-
- Fowler JE, Mills SE. Operable prostatic carcinoma: correlations among clinical stage, pathological stage, gleason histological score and early disease-free survival. J Urol. 1985 Jan;133(1):49–52. - PubMed
-
- Byar DP, Mostofi FK. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer. 1972 Jul;30(1):5–13. - PubMed
-
- Jewett HJ, Eggleston JC, Yawn DH. Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. J Urol. 1972 Jun;107(6):1034–40. - PubMed
-
- Freedland SJ, Aronson WJ, Presti JC, Jr, Amling CL, Terris MK, Trock B, Kane CJ. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004 Apr 15;100(8):1633–8. - PubMed
Publication types
MeSH terms
Grants and funding
- N01 CA004919/CA/NCI NIH HHS/United States
- CA37981/CA/NCI NIH HHS/United States
- U10 CA022433/CA/NCI NIH HHS/United States
- CA58416/CA/NCI NIH HHS/United States
- U10 CA027057/CA/NCI NIH HHS/United States
- N01 CA035176/CA/NCI NIH HHS/United States
- U10 CA012644/CA/NCI NIH HHS/United States
- CA04920/CA/NCI NIH HHS/United States
- CA46136/CA/NCI NIH HHS/United States
- CA35261/CA/NCI NIH HHS/United States
- U10 CA037981/CA/NCI NIH HHS/United States
- U10 CA004919/CA/NCI NIH HHS/United States
- N01 CA035431/CA/NCI NIH HHS/United States
- CA22433/CA/NCI NIH HHS/United States
- U10 CA046113/CA/NCI NIH HHS/United States
- CA12213/CA/NCI NIH HHS/United States
- CA12644/CA/NCI NIH HHS/United States
- CA20319/CA/NCI NIH HHS/United States
- U10 CA076447/CA/NCI NIH HHS/United States
- N01 CA032102/CA/NCI NIH HHS/United States
- CA66636/CA/NCI NIH HHS/United States
- U10 CA058416/CA/NCI NIH HHS/United States
- CA58658/CA/NCI NIH HHS/United States
- U10 CA014028/CA/NCI NIH HHS/United States
- N01 CA035119/CA/NCI NIH HHS/United States
- N01 CA046441/CA/NCI NIH HHS/United States
- CA21661/CA/NCI NIH HHS/United States
- CA14028/CA/NCI NIH HHS/United States
- CA58882/CA/NCI NIH HHS/United States
- CA45377/CA/NCI NIH HHS/United States
- U10 CA074647/CA/NCI NIH HHS/United States
- CA11083/CA/NCI NIH HHS/United States
- U10 CA066636/CA/NCI NIH HHS/United States
- CA58861/CA/NCI NIH HHS/United States
- CA35090/CA/NCI NIH HHS/United States
- CA76132/CA/NCI NIH HHS/United States
- CA46282/CA/NCI NIH HHS/United States
- U10 CA035261/CA/NCI NIH HHS/United States
- U10 CA035178/CA/NCI NIH HHS/United States
- CA76447/CA/NCI NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- U10 CA046282/CA/NCI NIH HHS/United States
- N01 CA035178/CA/NCI NIH HHS/United States
- N01 CA038926/CA/NCI NIH HHS/United States
- U10 CA067575/CA/NCI NIH HHS/United States
- N01 CA027057/CA/NCI NIH HHS/United States
- U10 CA046441/CA/NCI NIH HHS/United States
- U10 CA045377/CA/NCI NIH HHS/United States
- U10 CA021661/CA/NCI NIH HHS/United States
- U10 CA058882/CA/NCI NIH HHS/United States
- CA74647/CA/NCI NIH HHS/United States
- U10 CA020319/CA/NCI NIH HHS/United States
- CA46113/CA/NCI NIH HHS/United States
- U10 CA038926/CA/NCI NIH HHS/United States
- U10 CA042777/CA/NCI NIH HHS/United States
- U10 CA023318/CA/NCI NIH HHS/United States
- U10 CA035431/CA/NCI NIH HHS/United States
- U10 CA035119/CA/NCI NIH HHS/United States
- CA42777/CA/NCI NIH HHS/United States
- U10 CA011083/CA/NCI NIH HHS/United States
- N01 CA067575/CA/NCI NIH HHS/United States
- CA76429/CA/NCI NIH HHS/United States
- CA23318/CA/NCI NIH HHS/United States
- U10 CA035176/CA/NCI NIH HHS/United States
- U10 CA035090/CA/NCI NIH HHS/United States
- CA58723/CA/NCI NIH HHS/United States
- U10 CA058861/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical